; (C) the effective date of final regulations issued through Secretarial notice-and-comment rulemaking that take into consideration the findings and recommendations in the report from the Inspector General of the Department of Health and Human Services required under subsection (g)(3). . (c) Regulations To reduce duplicate discount risks Subsection (a)(5)(A) of section 340B of the Public Health Service Act ( 42 U.S.C. 256b ) is amended by adding at the end the following new clause: (iii) Not later than one year after the date of the enactment of this clause, the Secretary shall promulgate final regulations through notice-and-comment rulemaking, describing methodologies for State Medicaid programs and all covered entities under subsection (a)(4) to identify and bill drugs subject to an agreement under this section in a manner that ensures compliance with 340B Program prohibitions regarding duplicate discounts, including the duplicate discount prohibition under section 1927(j)(1) of the Social Security Act, to include the application of such prohibitions to Medicaid managed care enrollees. Such methodologies shall include the use of 340B-specific claims identifiers, and the provision of claims-level data by covered entities to States as well as manufacturers of covered outpatient drugs sufficient to identify claims that include drugs subject to an agreement under this section and to prevent duplicate discounts. . (d) Amount charged to low-Income patients (1) In general Subsection (a)(5) of section 340B of the Public Health Service Act ( 42 U.S.C. 256b ) is amended by adding at the end the following new subparagraphs: (E) Amount charged to low-income patients As a condition of certification or recertification under subparagraph (E) of paragraph (7), each covered entity described in subparagraph (L) or (M) of subsection (a)(4) must establish a sliding scale fee schedule for providing covered outpatient drugs that are subject to an agreement under this section, directly or under a contractual arrangement pursuant to